Clinical Trials Logo

Filter by:
  • Enrolling by invitation  
  • Page [1] ·  Next »
NCT ID: NCT06373393 Enrolling by invitation - Aortic Dissection Clinical Trials

SPIRIT: Study of the Patency of Spinal aRteries After the STABILISE Technique

SPIRIT
Start date: April 16, 2024
Phase:
Study type: Observational

The aim of the study is to evaluate the impact of the stent-assisted balloon-induced intimal disruption and relamination in aortic dissection repair (STABILISE) technique in the patency of intercostal and lumbar arteries detectable on computed tomography angiography (CTA) in patients with type B aortic dissection and its correlation with the occurrence of spinal cord ischaemia (SCI). Primary end-point: patency of the intercostal and lumbar arteries on follow-up CTA. Secondary end-point: spinal cord ischaemia

NCT ID: NCT06111014 Enrolling by invitation - Clinical trials for Neurodegenerative Diseases

Continuation Study for Latozinemab

Start date: December 8, 2023
Phase: Phase 3
Study type: Interventional

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

NCT ID: NCT05937009 Enrolling by invitation - Clinical trials for Community-dwelling Older Adults

12 Weeks Orienteering Program Exercise on Older Adults

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This study aims to determine the effects of an orientation exercise program addressed to old on physical-motor, cognitive, and affective competencies. This quasi-experimental study is a controlled trial involving an orientation exercise program. The program will run for 12 weeks (3 sessions per week). Participants will be clustered into two groups: the experimental group will perform the exercise orientation sessions, and the control group will maintain regular activities routines. Evaluations will be performed before and after the intervention. After the study is finished, the control group will attend a similar exercise program.

NCT ID: NCT05899673 Enrolling by invitation - Clinical trials for Alpha1-Antitrypsin Deficiency

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

Start date: August 8, 2023
Phase: Phase 3
Study type: Interventional

The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein. People who are currently taking part in or have completed previous fazirsiran studies (AROAAT2001 [NCT03945292] or AROAAT2002 [NCT03946449]) can continue to receive fazirsiran in this study. Participants will receive fazirsiran every 3 months for almost 2 years and will then be followed for an additional 6 months. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.

NCT ID: NCT05875090 Enrolling by invitation - Glaucoma Clinical Trials

Glaucoma Portugal Screening Trial

Glaucoma PoST
Start date: April 13, 2023
Phase: N/A
Study type: Interventional

Two primary care-based screening systems will be used to identify subjects with referrable glaucoma to hospital care. Subjects between 55 to 65 years old living in two primary care areas (urban area in Lisbon ; countryside setting in Minho) will be invited to a one-time assessment of optic disc and intraocular pressure (IOP). Criteria for referral will differ between centers, with one arm (Lisbon) using an artificial intelligence (AI) reading software of the optic disc picture, the other (Minho) will base their referral based on optical coherence tomography (OCT) retinal nerve fibre layer abnormality. A masked reading center will be established to set the ground truth for diagnosis. This pilot screening trial will explore the level of agreement between both systems as well as their cost effectiveness and identify diagnostic composite scores that could maximize the screening process. Secondary analyses will include the identification of population characteristics that increase effectivity of screening process as well as determining the population less likely to adhere to screening programmes.

NCT ID: NCT05817162 Enrolling by invitation - Clinical trials for Temporomandibular Joint Disorders

Temporomandibular Joint Arthrocentesis With Infiltration of PRP + Ropivacaine Versus PRP

Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

The infiltration of Platelet Rich Plasma (PRP) at the end of Temporomandibular Joint (TMJ) arthrocentesis is already an established procedure in the treatment of Temporomandibular Disorders (TMD). Arthrocentesis is a minimally invasive surgical procedure, which aims to eliminate the inflammatory mediators from the inside of the TMJ. PRP is an autologous concentrate of platelets and growth factors, derived from centrifugated blood. Several studies have described the benefits of PRP: it enhances wound healing because of the presence of cytokines and growth factors, and is also stimulates chondrocytes to biosynthesis of collagen. Ropivacaine is a local anesthetic that has been synthesized for use in infiltration anesthesia and to produce both peripheral and central block. Unlike one of its analogues, Bupivacaine, Ropivacaine anesthetize the sensory fibers without affecting the motor ones. The main goal of this investigation is to test the benefits of adding Ropivacaine to the infiltration of PRP in patients submitted to TMJ arthrocentesis.

NCT ID: NCT05619783 Enrolling by invitation - Clinical trials for Amyotrophic Lateral Sclerosis

Extension Study Evaluating The Safety And Tolerability of AMX0035

Start date: December 29, 2022
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the safety and tolerability of AMX0035 over 108 weeks of open label treatment for participants previously enrolled in Study A35-004 (PHOENIX).

NCT ID: NCT05589545 Enrolling by invitation - Prosthesis Survival Clinical Trials

PEEK Prostheses in the All-on-4 Concept Using Zygomatic Implants for Full-arch Rehabilitation.

PEEKPilotZyg
Start date: July 19, 2019
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the outcome of a Poly-ether-ether-ketone - acrylic resin prosthesis for full-arch rehabilitation of the atrophic maxillae through the All-on-4 Hybrid concept (standard and zygomatic implants) after one year of follow-up. The main question it aims to answer is: - What is the survival outcome of the full-arch implant-supported Poly-ether-ether-ketone - acrylic resin prosthesis? The participants already rehabilitated with dental implants will receive a Poly-ether-ehter-ketone prosthesis as a definitive prosthesis.

NCT ID: NCT05589532 Enrolling by invitation - Prosthesis Survival Clinical Trials

Single Tooth Implant-supported Fixed Prosthetic Rehabilitation Using PEEK.

PEEKPilotST
Start date: August 6, 2020
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the outcome of a Poly-ether-ether-ketone - used in single teeth implant-supported rehabilitations after one year of follow-up. The main question it aims to answer is: - What is the survival outcome of single teeth implant-supported prosthesis using Poly-ether-ether-ketone? The participants already rehabilitated with a single tooth dental implant will receive a definitive prosthesis incorporating Poly-ether-ehter-ketone.

NCT ID: NCT05589519 Enrolling by invitation - Prosthesis Survival Clinical Trials

Partial Implant-supported Rehabilitation Using PEEK

PEEKPilotSB
Start date: October 3, 2022
Phase: N/A
Study type: Interventional

The goal of this observational study is to evaluate the outcome of a Poly-ether-ether-ketone - used in partial implant-supported rehabilitations after one year of follow-up. The main question it aims to answer is: - What is the survival outcome of partial implant-supported prosthesis using Poly-ether-ether-ketone? The participants already rehabilitated with dental implants will receive a definitive 3 unit prosthesis incorporating Poly-ether-ehter-ketone.